157 related articles for article (PubMed ID: 19950226)
41. Influences of multiple genetic polymorphisms on ovarian cancer risk in Malaysia.
Velapasamy S; Alex L; Chahil JK; Lye SH; Munretnam K; Hashim NA; Ramzi NH; Nordin NM; Visvalingam V; Ler LW
Genet Test Mol Biomarkers; 2013 Jan; 17(1):62-8. PubMed ID: 23113749
[TBL] [Abstract][Full Text] [Related]
42. Polymorphisms in MicroRNA Binding Sites Predict Colorectal Cancer Survival.
Yang YP; Ting WC; Chen LM; Lu TL; Bao BY
Int J Med Sci; 2017; 14(1):53-57. PubMed ID: 28138309
[No Abstract] [Full Text] [Related]
43. Frequencies of single-nucleotide polymorphisms and mutations in the BRCA1 gene in patients with hereditary breast or ovarian cancer.
Karpukhin AV; Pospekhova NI; Lubchenko LN; Loginova AN; Khomich EV; Budilov AV; Sergeev AS; Zakhar'ev VM; Gar'kavtseva RF; Ginter EK
Dokl Biol Sci; 2002; 383():144-6. PubMed ID: 12053566
[No Abstract] [Full Text] [Related]
44. Breast cancer incidence rates among orthodox Jewish women.
Tkatch R; Schwartz K; Shore RD; Penner LA; Simon MS; Albrecht TL
J Immigr Minor Health; 2014 Oct; 16(5):1007-10. PubMed ID: 23584710
[TBL] [Abstract][Full Text] [Related]
45. Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer.
Sellers TA; Huang Y; Cunningham J; Goode EL; Sutphen R; Vierkant RA; Kelemen LE; Fredericksen ZS; Liebow M; Pankratz VS; Hartmann LC; Myer J; Iversen ES; Schildkraut JM; Phelan C
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):397-404. PubMed ID: 18268124
[TBL] [Abstract][Full Text] [Related]
46.
Shafique R; Mahjabeen I; Bibi K; Kalsoom F; Rizwan M; Ashraf NS; Mehmood A; Ul Haq MF; Abbasi SF; Saeed N; Kayani MA
Future Oncol; 2023 Sep; 19(28):1929-1943. PubMed ID: 37781867
[No Abstract] [Full Text] [Related]
47. microRNA-related single-nucleotide polymorphisms and breast cancer.
Bahreini F; Rayzan E; Rezaei N
J Cell Physiol; 2021 Mar; 236(3):1593-1605. PubMed ID: 32716070
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk.
Blitzblau RC; Weidhaas JB
Mol Diagn Ther; 2010 Dec; 14(6):335-42. PubMed ID: 21275451
[TBL] [Abstract][Full Text] [Related]
49. Personalised medicine and population health: breast and ovarian cancer.
Narod SA
Hum Genet; 2018 Oct; 137(10):769-778. PubMed ID: 30328515
[TBL] [Abstract][Full Text] [Related]
50. Towards a more precise and individualized assessment of breast cancer risk.
Wood ME; Farina NH; Ahern TP; Cuke ME; Stein JL; Stein GS; Lian JB
Aging (Albany NY); 2019 Feb; 11(4):1305-1316. PubMed ID: 30787204
[TBL] [Abstract][Full Text] [Related]
51. Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing.
Graves KD; Peshkin BN; Luta G; Tuong W; Schwartz MD
Public Health Genomics; 2011; 14(3):178-89. PubMed ID: 21464556
[TBL] [Abstract][Full Text] [Related]
52. The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians.
Catucci I; Verderio P; Pizzamiglio S; Bernard L; Dall'olio V; Sardella D; Ravagnani F; Galastri L; Barile M; Peissel B; Zaffaroni D; Manoukian S; Radice P; Peterlongo P
Breast Cancer Res Treat; 2012 Jun; 133(2):805-7. PubMed ID: 22415478
[No Abstract] [Full Text] [Related]
53. Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer.
Kim S; Hagemann A; DeMichele A
Immunol Invest; 2009; 38(3-4):324-40. PubMed ID: 19811442
[TBL] [Abstract][Full Text] [Related]
54. SNPs for breast cancer risk assessment.
Cuzick J; Brentnall A; Dowsett M
Oncotarget; 2017 Nov; 8(59):99211-99212. PubMed ID: 29245890
[No Abstract] [Full Text] [Related]
55. Comprehensive assessment of the association between miRNA polymorphisms and gastric cancer risk.
Xu Q; Liu JW; Yuan Y
Mutat Res Rev Mutat Res; 2015; 763():148-60. PubMed ID: 25795117
[TBL] [Abstract][Full Text] [Related]
56. Ethnicity modifies the association between functional microRNA polymorphisms and breast cancer risk: a HuGE meta-analysis.
Chen QH; Wang QB; Zhang B
Tumour Biol; 2014 Jan; 35(1):529-43. PubMed ID: 23982873
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA sequence polymorphisms and the risk of different types of cancer.
Hu Y; Yu CY; Wang JL; Guan J; Chen HY; Fang JY
Sci Rep; 2014 Jan; 4():3648. PubMed ID: 24413317
[TBL] [Abstract][Full Text] [Related]
58. Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients.
Pastrello C; Polesel J; Della Puppa L; Viel A; Maestro R
Carcinogenesis; 2010 Dec; 31(12):2124-6. PubMed ID: 20810544
[TBL] [Abstract][Full Text] [Related]
59. hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population.
Omrani M; Hashemi M; Eskandari-Nasab E; Hasani SS; Mashhadi MA; Arbabi F; Taheri M
Biomark Med; 2014; 8(2):259-67. PubMed ID: 24521023
[TBL] [Abstract][Full Text] [Related]
60. Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies.
Ma XP; Zhang T; Peng B; Yu L; Jiang de K
PLoS One; 2013; 8(11):e79584. PubMed ID: 24278149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
